MO · Q2 2026 Earnings

Cautious

Altria

Reported July 30, 2026

30-second summary

Altria delivered Q2 FY2026 non-GAAP EPS of $1.48 (+2.8% YoY) on revenue of $6.11B (+0.1% YoY). The real news is the guidance: management raised the low end of FY2026 adjusted EPS to $5.61–$5.72 (from $5.56–$5.72), narrowed the growth range to 3.5%–5.5%, and — critically — reintroduced FY capex guidance at $375M–$450M, roughly $75M above last year's withdrawn $300M–$375M framework. The H2 cadence was walked back again: what was "H1/H2 balanced" last quarter is now "more balanced between Q3 and Q4," implying Q3 decelerates.

Headline numbers

EPS

Q2 FY2026

$1.48

-1.3% vs est.

Revenue

Q2 FY2026

$6.11B

+0.1% YoY

+14.2% vs est.

Gross margin

Q2 FY2026

62.5%

Operating margin

Q2 FY2026

51.3%

Key financials

Q2 FY2026

Metric	Q2 FY2026	Q2 FY2025	YoY	Q1 FY2026	QoQ
Revenue	$6.11B	$6.10B	+0.1%	$5.43B	+12.6%
EPS	$1.48	$1.44	+2.8%	$1.32	+12.1%
Gross margin	62.5%	63.0%	-50bps	64.6%	-210bps
Operating margin	51.3%	52.9%	-160bps	54.4%	-310bps

Guidance

Raised FY2026 adjusted diluted EPS guidance low-end by $0.05 to $5.61–$5.72 and narrowed growth range to 3.5%–5.5%, while introducing capex guidance of $375–$450M.

Guidance is issued for both next quarter and the full year. Both may appear below.

New guidance

Metric	Period	Guide	YoY
Capital Expenditures	FY 2026	$375 million to $450 million	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Adjusted Diluted EPS	FY 2026	$5.56 to $5.72	$5.61 to $5.72	+$0.05 at low end	Raised
Adjusted Diluted EPS Growth Rate	FY 2026	2.5% to 5.5% YoY	3.5% to 5.5% YoY	+1.0 percentage point at low end	Raised

Segment performance

Q2 FY2026

Segment	Q2 FY2026	Q2 FY2025	YoY
Smokeable Products	$5.392B	$5.357B	+0.7%
Oral Tobacco Products	$0.713B	$0.753B	-5.3%

Platform metrics

Q2 FY2026

Segment	Q2 FY2026	Q2 FY2025	YoY
Domestic Cigarette Shipment Volume Growth	-3.2%	—	—
Marlboro Retail Share	39.5%	—	—
on! Retail Share of Nicotine Pouch Category	14.4%	—	—
Nicotine Pouch Category Share of Oral Tobacco	59.9%	—	—

Profitability

Q2 FY2026

Segment	Q2 FY2026	Q2 FY2025	YoY
Adjusted OCI Margin - Smokeable Products	64.8%	—	—
Adjusted OCI Margin - Oral Tobacco Products	66.7%	—	—
Adjusted Diluted EPS Growth YoY	2.8%	—	—

Other KPIs

Q2 FY2026

Segment	Q2 FY2026	Q2 FY2025	YoY
Share Repurchases (Q2)	$55 million	—	—

Management tone

Q2 FY2025 conditional-on-enforcement narrowing → Q3 FY2025 raised floor + pushed ACE to 2027 → Q4 FY2025 $1.3B eVapor impairment and explicit retreat → Q1 FY2026 reaffirmed guide with new macro caveats → Q2 FY2026 narrow raise but H2 cadence walked down again + capex step-up.

No transcript available for this quarter — the observations below are drawn from the press release and cross-quarter guidance framework only.

The H2 cadence framing has been walked down again, and each iteration transferred bar weight into a later quarter. Q1 FY2026 framed FY2026 as "more balanced between H1 and H2." Q2 FY2026 further narrows to "the second-half benefit to be more balanced between the third and fourth quarters." Read literally, that language means Q3 will not carry the H2 growth on its own — meaningful contribution now lands in Q4. Combined with only +2.8% YoY EPS growth in Q2 against a FY midpoint of +4.5%, the math requires Q4 to do heavy lifting. Any Q3 miss would put the newly-raised $5.61 floor at real risk.

The reappearance of FY capex guidance at a materially higher level than what was withdrawn is a quiet admission. Last quarter tax rate, capex, and D&A all disappeared from the FY framework without explanation. This quarter capex returns at $375M–$450M — the midpoint is ~$75M above the withdrawn midpoint. Per management, the increase primarily reflects investments to support the USSTC Facilities Consolidation. Tax rate and D&A remain absent from the disclosure.

The buyback pace collapse to $55M is the most concrete negative signal on the print. Q1 was $280M; Q2 was $55M — an 80% sequential drop. With $665M remaining under the $2B authorization expiring Dec 31, 2026, the run-rate implied to fully execute the program is ~$165M/quarter for H2 FY2026. Q2's pace is a fraction of that. Either the pace steps up sharply in H2 or MO is de-facto letting the authorization lapse — which would reverse the "cleanest bull signal on the print" narrative from Q3 FY2025 when the buyback was doubled to $2B.

Answers to last quarter's watch list

Q2 FY2026 EPS in absolute dollars. Non-GAAP EPS of $1.48 grew 2.8% YoY vs Q2 FY2025's $1.44 — below the mid-single-digit YoY growth bar management's "balanced H1/H2" framing implied. The FY range was raised only at the low end. Status: Resolved negatively

Whether tax rate, capex, and D&A guidance lines reappear in Q2 disclosure. Capex reappeared at $375M–$450M — but at a midpoint ~$75M above the withdrawn range, extending the capex step-up narrative. Tax rate and D&A remain absent. Partial return of transparency, on worse terms for the capex line. Status: Resolved mixed — capex back at a higher level; tax and D&A still missing

Cigarette shipment volume decline trajectory from -2.4% (-4% ex inventory). Q2 domestic cigarette shipment volume declined 3.2% YoY (an estimated 4.5% ex inventory) — a reversal of the moderation trend management leaned on last quarter. Suggests the Q1 improvement was inventory-aided or one-quarter optical. Status: Resolved negatively

on! total oral category share from 7.8% and pouch-category share from 13.4%. on!'s total oral-category share was 8.6% (+30bps YoY, +80bps QoQ) and pouch-category share was 14.4% (+100bps QoQ but -170bps YoY). QoQ improvement on both lines is directional validation for on! PLUS; the YoY pouch decline shows the sub-category share hole isn't yet closed. Status: Resolved mixed

Oral Tobacco adj. OCI margin trajectory from 67.4%. Q2 Oral Tobacco adj. OCI margin was 66.7%, down 70bps QoQ from Q1's 67.4% and down 200bps YoY. Margin pressure persisted rather than recovered. Status: Resolved negatively

First disclosed on! PLUS volume or share data point. Management disclosed that Helix expanded on! PLUS to 120,000 stores nationwide with line extensions planned — a distribution data point, not a share or volume data point. Still no standalone on! PLUS revenue, volume, or share figure. Status: Continue monitoring

NJOY ACE re-entry timing. The press release restates that guidance contemplates NJOY ACE does not return to the marketplace in 2026. Status: Continue monitoring

What to watch into next quarter

Q3 FY2026 non-GAAP EPS vs Q3 FY2025's $1.45. With the H2 cadence now framed as "balanced Q3/Q4," Q3 needs to grow at least mid-single digits YoY to keep the $5.61 floor credible. Q3 EPS below $1.48 would put the raise-just-made at immediate risk.

Oral Tobacco segment revenue trajectory. Q2's -5.3% reversal from Q1's +2.3% is the biggest surprise on the print. If Q3 stays negative, the smoke-free transition thesis is under real pressure and the 66.7% segment OCI margin is next to break.

Buyback pace vs the $665M remaining authorization. Q2's $55M pace, if sustained, means MO does not fully execute the program before its Dec 2026 expiry. A Q3 step-up back toward $165M+ would signal capital-return discipline; another sub-$100M quarter would confirm the capex step-up is crowding out buybacks.

Whether tax rate and D&A guidance lines return in the Q3 disclosure. Two of three withdrawn line items are still missing. Continued absence means the FY2026 P&L still has meaningful hidden variables.

on!'s pouch-category share from 14.4% (-170bps YoY). A second consecutive sequential gain — and, more importantly, a narrowing of the YoY deficit — would validate on! PLUS as a genuine stabilizer within the pouch sub-category.

Any first quantitative on! PLUS data point — revenue, volume, or standalone share. Management is now four quarters into the on! PLUS launch and has still not disclosed a standalone metric. Continued silence past the one-year anniversary is itself a negative signal.

Whether capex guidance drifts higher again in Q3. The Q2 reintroduction at $375M–$450M is already ~$75M above the withdrawn framework. Another step-up in Q3 would indicate the USSTC Facilities Consolidation is running over the FY2025 planning assumption.

Sources

Altria Q2 FY2026 Earnings Press Release (Exhibit 99.1), SEC filing: https://www.sec.gov/Archives/edgar/data/764180/000076418026000093/exhibit991erq22026.htm
Altria Q1 FY2026 Earnings Press Release (Exhibit 99.1), SEC filing: https://www.sec.gov/Archives/edgar/data/764180/000076418026000056/exhibit991erq12026.htm
Altria Q4 FY2025 Earnings Press Release (Exhibit 99.1), SEC filing: https://www.sec.gov/Archives/edgar/data/764180/000076418026000007/exhibit991erq42025.htm

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.